Indian stocks: Visit www.stage2stocks.com →

Neuraxis, Inc.

Stage 2 · Advancing · week 3

As of Oct 22, 2026, Neuraxis is in Stage 2, the uptrend phase, now in week 3 (since Oct 8, 2026). It closed at $7.60, 13.7% below its 52-week high and above its 200-day average, which is rising.

NeurAxis, Inc., a medical technology company, focuses on developing neuromodulation therapies to address chronic and debilitating conditions in children and adults in the United States. More about the company

$7.60
-4.04% today
$95.4M · Micro cap
Market Neutral — Building

Pro read

Pro

Our read

Early entry: still early enough in its move

Setup score

—

Momentum

Steady

Edge

—

Setup-score rank among Stage 2 peers: #1 of 110 in Biotechnology · #1 of 272 in Health Care

Is NRXS early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…
Stage Cycle Timeline2023-08-16 → 2026-10-22
S? 40w
S4 30w
S2 24w
S3 15w
2023-08-162026-10-22
S1S2S3S4Setup score (0–10, dashed line at 5)
S? 40w → S4 1w → S3 13w → S2 5w → S3 2w → S4 30w → S1 8w → S2 4w → S3 6w → S2 11w → S3 3w → S2 24w → S3 15w → S2 2w current
Total tracked: 165 weeks across 14 stage runs.

NRXS among Biotechnology46th of 591 by relative strength

All 591 →
Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#StockStageRS1M
1GTBPStage 2 · wk 799−22.3%
2IOVAStage 2 · wk 1899+38.8%
3SLSStage 3 · wk 499−1.5%
4MRNAStage 2 · wk 1799+11.3%
5TWSTStage 2 · wk 3999−14.5%
6KODStage 2 · wk 499+172.1%
7ERASStage 3 · wk 599+0.7%
8CLYMStage 3 · wk 399−15.8%
…46NRXSStage 2 · wk 395+4.0%
vs 52W High
-13.7%
$2.31 lo$8.81 hi
13.7% below 52W high, pullback range
How far this stock is from its 52-week high. A pullback of 3–20% while Stage 2 structure holds is typically a better entry than chasing near the high.
Stage Maturity
Week 3
1w13w26w
Week 3, fresh breakout
How long this stock has been in Stage 2. The sweet spot is mid-run: long enough to prove the structure holds, not so long that it's extended. Very fresh moves (weeks 1–4) often need more time to confirm.
vs 200 DMA
15.3%
200 DMA: $6.59 · rising
Long-term trend anchor. When the stock and the S&P 500 are both above their 200-day averages, the backdrop supports continuation.
Rel Volume
0.64x
vs 50-day avg
Low vol (0.5–1x) on pullbacks = resting, not being sold. High vol on breakouts = commitment. Volume spike on down days is a warning sign.
Trend Health
↑
Short-term trend rising strongly
Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.
1M
+4.0%
3M
+11.8%
6M
+2.0%
YTD
+70.4%
1Y
+105.4%
Scan Membership
Breakout Watch
Latest: 2024-09-03
A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.
Recent Stage Timeline
2026-10-22S2
Wk 3 · Vol 0.64x
2026-10-21S2
Wk 2 · Vol 0.46x
2026-10-20S2
Wk 2 · Vol 0.40x
2026-10-19S2
Wk 2 · Vol 1.39x
2026-10-16S2
Wk 2 · Vol 1.68x
2026-10-15S2
Wk 2 · Vol 9.78x
2026-10-14S2
Wk 1 · Vol 1.51x
2026-10-13S2
Wk 1 · Vol 1.03x
2026-10-12S2
Wk 1 · Vol 0.66x
2026-10-09S2
Wk 1 · Vol 0.49x
2026-10-08S23→2
Wk 1 · Vol 0.25x
2026-10-07S3
Wk 16 · Vol 0.56x
Moving averages & range
50 DMA
$6.70
200 DMA
$6.59
52W High
$8.81
52W Low
$2.31
5D Low
$7.60
Resistance levels (recent highs)
20d High
$7.92
60d High
$7.92
120d High
$8.81
250d High
$8.81
Next resistance
+4.2%
to 20d High
ROE
-139.8%
Profit margin -144.4%
Dividend Yield
0.00%
P/B 14.1

Neuraxis: quick answers

What stage is Neuraxis in?

As of Oct 22, 2026, Neuraxis (NRXS) is in Stage 2, the uptrend phase. It entered Stage 2 on Oct 8, 2026 and is in week 3. What the four stages mean

Is Neuraxis in an uptrend?

Yes. Neuraxis is in a Stage 2 uptrend. It trades 15.3% above its 200-day average, which is rising.

How far is Neuraxis from its 52-week high?

Neuraxis closed at $7.60 on Oct 22, 2026, 13.7% below its 52-week high of $8.81. Its 52-week low is $2.31.

How has Neuraxis performed over the past year?

As of Oct 22, 2026, Neuraxis is up 105.4% over the past year and up 70.4% so far in 2026.

Which sector and industry is Neuraxis in?

Neuraxis is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

NeurAxis, Inc., a medical technology company, focuses on developing neuromodulation therapies to address chronic and debilitating conditions in children and adults in the United States. It offers IB-Stim, a percutaneous electrical nerve field stimulation system intended to be used in patients 8 years of age with functional abdominal pain associated with irritable bowel syndrome (IBS), functional dyspepsia (FD) and associated FD nausea symptoms. The company also offers rectal expulsion device, a screening tool that helps to detects evacuation disorders. It sells its products to healthcare companies, such as hospitals and clinics. The company was formerly known as Innovative Health Solutions, Inc. and changed its name to NeurAxis, Inc. in March 2022. NeurAxis, Inc. was founded in 2011 and is headquartered in Carmel, Indiana.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.